Bill Wilson, MD: GLP-1s and GIPs Show Promise Beyond Diabetes—Doctors Prescribing Off-Label #obesity
Short excerpt from a YouTube interview (Dr. Ron Najafi interviewing Dr. Bill Wilson) discussing GLP-1 receptor agonists and GIP/GLP-1 combination drugs. Wilson reports these agents are established for type 2 diabetes and widely used for obesity, while also showing emerging benefits across multiple organ systems (neurodegenerative disorders, cardiac, renal, hepatic). He describes GIP addition as enhancing GLP-1 effects and notes many other indications are currently off-label and prescribed at physicians' discretion.
Chapters
More from Dr.
Hippocrates said, let thy food be thy medicine #obesity #metabolicsyndrome #lustig #shorts #health
Bill Wilson, MD: Why GLP-1 Drugs Are Overpriced—and How Compounding and Competition Could Fix It
Nitrosamine in Pharmaceutical Products? A Deep Dive into Risk Management by Ron Najafi, Ph.D.
The Subcellular Processes That Belie All Chronic Disease. The Hateful (or Grateful) Eight #lustig
Bill Wilson, MD: GLPs May Reverse Carb Syndrome—Helping Patients Reach Zero and Sustain with Diet
Why Everything You Knew About Obesity Is Wrong | Dr. Robert Lustig on Sugar & Metabolic Syndrome
Robert Lustig, MD: How Fructose Fuels Fatty Liver, Oxidative Stress, and Metabolic Disease #fructose
Robert Lustig, MD: The 3 Types of Fat Fueling Insulin Resistance and Disease #insulin resistance
Bill Wilson, MD: GLPs May Reverse CARB Syndrome. Helping Patients Reach Zero and Sustain with Diet